Relapse Multiple Myeloma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for relapse multiple myeloma. 24 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
24
Active US patents
60/100
Avg vulnerability
$1.3B
Annual revenue covered

Originators in Relapse Multiple Myeloma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Amgen 24 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating relapse multiple myeloma. Each bar = one year. Y-axis scaled to peak year (6 patents).

3
26
6
27
3
28
3
29
3
30
6
33

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Kyprolis
carfilzomib
 Amgen 24 60 $1.3B 2026-07-20

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7417042 Kyprolis other 80 2027-01-20
7417042 Kyprolis other 80 2027-01-20
7417042 Kyprolis other 80 2027-01-20
RE47954 Kyprolis method of use 76 2029-10-21
RE47954 Kyprolis method of use 76 2029-10-21
RE47954 Kyprolis method of use 76 2029-10-21
7737112 Kyprolis other 75 2028-06-07
7737112 Kyprolis other 75 2028-06-07
7737112 Kyprolis other 75 2028-06-07
RE47954 Kyprolis other 68 2030-04-21

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7417042 Kyprolis composition of matter 22 2026-07-20
7417042 Kyprolis composition of matter 22 2026-07-20
7417042 Kyprolis composition of matter 27 2026-07-20
9493582 Kyprolis formulation 42 2033-02-27
9493582 Kyprolis formulation 42 2033-02-27
9493582 Kyprolis formulation 42 2033-02-27
7737112 Kyprolis formulation 55 2027-12-07
7737112 Kyprolis formulation 55 2027-12-07
7737112 Kyprolis formulation 60 2027-12-07
9493582 Kyprolis other 62 2033-08-27

Related